Cytoimmune Therapeutics

MitoImmune Therapeutics Inc. is a biopharmaceutical company specializing in the discovery and development of innovative drugs that target mitochondria to create new potential groundbreaking therapies. The company was established in August 2018 and focuses on addressing mitochondrial dysfunction-related necrotic and inflammatory diseases in order to enhance healthy lifespan. Its primary program is based on the pioneering scientific discoveries of its founder Soon Ha Kim at LG Life Sciences, which was acquired by LG Chem in late 2017.